Selumetinib (AZD6244)

Name: Selumetinib (AZD6244)
Brand: Selleck Chemicals
SKU: S1008
Rating: 5 (562 reviews)

For research use only.

Catalog No.S1008 Synonyms: ARRY-142886

562 publications

Selumetinib (AZD6244) Chemical Structure

CAS No. 606143-52-6

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Selleck's Selumetinib (AZD6244) has been cited by 562 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Nature, 2020, 588(7838):509-514

PubMed: 32927473 ( click the link to review the publication )

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Med, 2019, 25(1):130-140

PubMed: 30510251 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Mater, 2018, 17(4):361-368

PubMed: 29403054 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cell, 2018, 172(4):857-868

PubMed: 29336889 ( click the link to review the publication )

Nat Med, 2018, 24(7):961-967

PubMed: 29808006 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):439-452

PubMed: 30205046 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):119-126

PubMed: 27870838 ( click the link to review the publication )

Gastroenterology, 2017, 152(5):1161-1173

PubMed: 27956228 ( click the link to review the publication )

Nature, 2016, 10.1038/nature19347

PubMed: 27580028 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(2):184-191

PubMed: 26780180 ( click the link to review the publication )

Gastroenterology, 2016, 150(4):918-30

PubMed: 26677984 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Nat Genet, 2015, 47(9):996-1002

PubMed: 26214590 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )
Cancer Cell, 2015, 27(2):240-56

PubMed: 25600339 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):94-109

PubMed: 24265153 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1214-29

PubMed: 25256614 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 3(3):350-62

PubMed: 23288408 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(5):414-24

PubMed: 22588879 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Nat Genet, 2011, 43(11):1119-26

PubMed: 21946352 ( click the link to review the publication )

Nature, 2010, 16;468(7326):968-72.

PubMed: 21107320 ( click the link to review the publication )

J Extracell Vesicles, 2021, 10(8):e12091

PubMed: 34136107 ( click the link to review the publication )

Cancer Res, 2021, canres.1895.2020

PubMed: 33402388 ( click the link to review the publication )

Cell Rep, 2021, 35(11):109238

PubMed: 34133937 ( click the link to review the publication )

Cell Rep, 2021, 35(8):109181

PubMed: 34038737 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01917-z

PubMed: 34247190 ( click the link to review the publication )

Cancer Lett, 2021, 502:25-33

PubMed: 33440231 ( click the link to review the publication )

Cancer Lett, 2021, 510:37-47

PubMed: 33872695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):22

PubMed: 33413561 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)862

PubMed: 33670725 ( click the link to review the publication )
Cancers (Basel), 2021, 13(6)1408

PubMed: 33808771 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)829

PubMed: 33669371 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Front Immunol, 2021, 12:657071

PubMed: 33995374 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0965.2020

PubMed: 34158345 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:661122

PubMed: 33937262 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1987-1996

PubMed: 33686706 ( click the link to review the publication )

J Proteome Res, 2021, 10.1021/acs.jproteome.1c00444

PubMed: 34292731 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Cell Signal, 2021, S0898-6568(21)00123-6

PubMed: 33933583 ( click the link to review the publication )

J Gastrointest Oncol, 2021, 12(3):1020-1030

PubMed: 34295553 ( click the link to review the publication )

Int J Med Sci, 2021, 18(9):2008-2016

PubMed: 33850471 ( click the link to review the publication )

Arch Virol, 2021, 166(5):1433-1438

PubMed: 33683474 ( click the link to review the publication )

J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )

In Vivo, 2021, 35(2):721-729

PubMed: 33622865 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)555

PubMed: 33535609 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Cell Biosci, 2021, 11(1):40

PubMed: 33622407 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

Eur Respir J, 2020, 8;2000522

PubMed: 32513782 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Dev Cell, 2020, 52(5):563-573

PubMed: 32032547 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.0448.2020

PubMed: 32605999 ( click the link to review the publication )

Cell Rep, 2020, 31(2):107514

PubMed: 32294432 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 14

PubMed: 32291414 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Oncogene, 2020, 39(15):3218-3225

PubMed: 32051554 ( click the link to review the publication )

Oncogene, 2020, 39(3):703-717

PubMed: 31541192 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(7):E1744

PubMed: 32629964 ( click the link to review the publication )

PLoS Pathog, 2020, 16(2):e1008307

PubMed: 32069328 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Br J Cancer, 2020, 22

PubMed: 32439932 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000657R

PubMed: 33124742 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0706

PubMed: 33208393 ( click the link to review the publication )

Development, 2020, 147(23)dev192351

PubMed: 33144395 ( click the link to review the publication )

Mol Cancer Ther, 2020, 13;molcanther11722019

PubMed: 32404410 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )
Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0664

PubMed: 33106373 ( click the link to review the publication )

Front Oncol, 2020, 10:1482

PubMed: 33042794 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7649

PubMed: 33081092 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):21985

PubMed: 33319783 ( click the link to review the publication )

J Biol Chem, 2020, 30 pii: jbc

PubMed: 32358059 ( click the link to review the publication )

Cancer Commun (Lond), 2020, 10.1002/cac2.12092

PubMed: 32888253 ( click the link to review the publication )

J Ethnopharmacol, 2020, 251:112535

PubMed: 31926315 ( click the link to review the publication )

Chem Biol Interact, 2020, 315:108910

PubMed: 31790661 ( click the link to review the publication )

Transl Oncol, 2020, 14(1):100920

PubMed: 33137541 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Pediatr Blood Cancer, 2020, e28639

PubMed: 32975370 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

J Chemother, 2020, 32(8):437-444

PubMed: 33052075 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:610

PubMed: 32754596 ( click the link to review the publication )

Cell Rep Med, 2020, 1(8):100131

PubMed: 33294856 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

J Pathol, 2020, e5503

PubMed: 32613636 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, S2352-345X(20)30117-X

PubMed: 32771388 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0609-7

PubMed: 32778845 ( click the link to review the publication )
Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158

PubMed: 32034077 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Viruses, 2020, 12(10)E1128

PubMed: 33028008 ( click the link to review the publication )

Arch Virol, 2020, 10.1007/s00705-020-04524-7

PubMed: 31942645 ( click the link to review the publication )

Gastroenterology, 2019, 157(3):823-837

PubMed: 31078621 ( click the link to review the publication )

Gastroenterology, 2019, 156(3):577-581

PubMed: 30391471 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

J Clin Invest, 2019, 10.1172/JCI128678

PubMed: 31805013 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:2987

PubMed: 31278260 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5549

PubMed: 31804471 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-4145

PubMed: 31285371 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Dev Cell, 2019, 51(5):602-616.e12

PubMed: 31794718 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2494-2510

PubMed: 30862719 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Rep, 2019, 27(3):806-819

PubMed: 30995478 ( click the link to review the publication )

Cell Rep, 2019, 29(1):118-134

PubMed: 31577942 ( click the link to review the publication )

Thyroid, 2019, 29(1):79-92

PubMed: 30398411 ( click the link to review the publication )
Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Oncogene, 2019, 38(18):3402-3414

PubMed: 30643193 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

EBioMedicine, 2019, 49:106-117

PubMed: 31668570 ( click the link to review the publication )

Stem Cell Reports, 2019,

PubMed: 31231022 ( click the link to review the publication )

Cancer Lett, 2019, 442:53-67

PubMed: 30391781 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 18;38(1):85

PubMed: 30777101 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31652979 ( click the link to review the publication )

PLoS Pathog, 2019,

PubMed: 30716130 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12812

PubMed: 31323160 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Br J Cancer, 2019, 121(9):758-767

PubMed: 31551581 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31766464 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31409052 ( click the link to review the publication )

PLoS Genet, 2019, 15(4):e1008077

PubMed: 30969964 ( click the link to review the publication )

Front Immunol, 2019, 10:2020

PubMed: 31507609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Mol Oncol, 2019, 13(7):1467-1489

PubMed: 30919591 ( click the link to review the publication )

Cancer Sci, 2019, 110(8):2529-2539

PubMed: 31119819 ( click the link to review the publication )

Oncogenesis, 2019, 8(9):50

PubMed: 31492847 ( click the link to review the publication )

Transl Psychiatry, 2019, 9(1):306

PubMed: 31740729 ( click the link to review the publication )
Lab Invest, 2019, 10.1038/s41374-019-0274-1

PubMed: 31201369 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(1):L20-L34

PubMed: 30260287 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0268-y

PubMed: 31316177 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(1):36-46

PubMed: 31048548 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23123

PubMed: 31571292 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1159

PubMed: 31649535 ( click the link to review the publication )

Int J Oncol, 2019, 54(3):1123-1133

PubMed: 30747223 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(1):349-357

PubMed: 30682205 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

Cell Cycle, 2019, 18(13):1513-1522

PubMed: 31135266 ( click the link to review the publication )

Cell Cycle, 2019, 18(5):596-604

PubMed: 30724698 ( click the link to review the publication )

J Mol Endocrinol, 2019, 63(3):199-213

PubMed: 31416049 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(8):1015-1025

PubMed: 31141756 ( click the link to review the publication )

Pathol Oncol Res, 2019, 25(2):769-775

PubMed: 30706361 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):3569-3575

PubMed: 30867799 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )
JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Br J Cancer, 2019, 10.1038/s41416-019-0673-5

PubMed: 31839677 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):201-211

PubMed: 31865182 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

Heliyon, 2019, 6(1):e03031

PubMed: 31909243 ( click the link to review the publication )

Sci Transl Med, 2018, 10(450)

PubMed: 30021885 ( click the link to review the publication )

Cell Res, 2018, 28(7):719-729

PubMed: 29795445 ( click the link to review the publication )

Mol Cell, 2018, 70(5):949-960

PubMed: 29861159 ( click the link to review the publication )

Mol Psychiatry, 2018, 23(2):444-458

PubMed: 28070119 ( click the link to review the publication )

Nat Commun, 2018, 9(1):579

PubMed: 29422527 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5416

PubMed: 30575746 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Nat Commun, 2018, 9(1):28

PubMed: 29295999 ( click the link to review the publication )

J Exp Med, 2018, 215(6):1693-1708

PubMed: 29769248 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(19):4854-4864

PubMed: 29945997 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6367-6382

PubMed: 30135148 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Genome Med, 2018, 10(1):90

PubMed: 30482246 ( click the link to review the publication )

Biomaterials, 2018, 156:258-273

PubMed: 29222974 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

Theranostics, 2018, 8(8):2134-2146

PubMed: 29721068 ( click the link to review the publication )

Cancer Res, 2018, 78(6):1444-1456

PubMed: 29321164 ( click the link to review the publication )
Int J Cancer, 2018, 142(2):381-391

PubMed: 28921565 ( click the link to review the publication )

Oncogene, 2018, 37(39):5340-5354

PubMed: 29858603 ( click the link to review the publication )

Cancer Lett, 2018, 414:268-277

PubMed: 29179997 ( click the link to review the publication )

Cancers (Basel), 2018, 10(11)

PubMed: 30373214 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1052

PubMed: 30323190 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Br J Cancer, 2018, 119(6):713-723

PubMed: 30116025 ( click the link to review the publication )

J Clin Med, 2018, 7(5)

PubMed: 29762469 ( click the link to review the publication )

Cancer Discov, 2018, 8(10):1237-1249

PubMed: 30045908 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 49(4):1499-1511

PubMed: 30205377 ( click the link to review the publication )

Bioinformatics, 2018, 34(17):i997-i1004

PubMed: 30423075 ( click the link to review the publication )

Bioinformatics, 2018, 34(23):4079-4086

PubMed: 29931053 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2329-2340

PubMed: 30166401 ( click the link to review the publication )

Br J Haematol, 2018, 182(6):921-924

PubMed: 28771685 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3816-3825

PubMed: 30343534 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30018229 ( click the link to review the publication )

Sci Rep, 2018, 8(1):850

PubMed: 29339801 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

J Biol Chem, 2018, 293(23):9113-9123

PubMed: 29540478 ( click the link to review the publication )

Front Pharmacol, 2018, 8:988

PubMed: 29379440 ( click the link to review the publication )
Mol Cell Endocrinol, 2018, 474:20-34

PubMed: 29428395 ( click the link to review the publication )

Cell Signal, 2018, 44:127-137

PubMed: 29329780 ( click the link to review the publication )

Cell Signal, 2018, 42:11-20

PubMed: 28986121 ( click the link to review the publication )

Am J Physiol, Cell Physiol, 2018,

PubMed: 30257106 ( click the link to review the publication )

Cell Cycle, 2018, 17(4):428-438

PubMed: 29468929 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Med Sci Monit, 2018, 24:8048-8055

PubMed: 30414267 ( click the link to review the publication )

Med Sci Monit, 2018, 24:3002-3010

PubMed: 29737325 ( click the link to review the publication )

Exp Lung Res, 2018, 44(7):332-343

PubMed: 30676129 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):326-334

PubMed: 29928418 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Nat Methods, 2018, 15(9):732-740

PubMed: 30127506 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):31

PubMed: 29348467 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):542

PubMed: 29739364 ( click the link to review the publication )

Cancer Discov, 2018, 8(11):1458-1473

PubMed: 30185628 ( click the link to review the publication )

Oncotarget, 2018, 9(74):33995-34008

PubMed: 30338041 ( click the link to review the publication )

Gut, 2017, 66(6):1106-1115

PubMed: 27670374 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2081-2090

PubMed: 28504649 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(21):6567-6579

PubMed: 28765329 ( click the link to review the publication )

Neuro Oncol, 2017, 20(6):764-775

PubMed: 29136244 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Int J Cancer, 2017, 140(12):2758-2770

PubMed: 27813079 ( click the link to review the publication )
Cancer Lett, 2017, 408:130-137

PubMed: 28866094 ( click the link to review the publication )

Br J Cancer, 2017, 116(8):1065-1076

PubMed: 28301874 ( click the link to review the publication )

Cancer Discov, 2017, 7(4):369-379

PubMed: 28122867 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

J Mater Chem B, 2017, 5(20):3658-3666

PubMed: 32264054 ( click the link to review the publication )

Sci Rep, 2017, 7:44123

PubMed: 28276530 ( click the link to review the publication )

J Steroid Biochem Mol Biol, 2017, 165(Pt B):258-267

PubMed: 27369115 ( click the link to review the publication )

J Biol Chem, 2017, 292(10):3970-3976

PubMed: 28179426 ( click the link to review the publication )

Urol Oncol, 2017, 35(1):32.e9-32.e16

PubMed: 27692847 ( click the link to review the publication )

Front Physiol, 2017, 7:682

PubMed: 28149280 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Biochemistry, 2017, 56(34):4449-4456

PubMed: 28574701 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184861

PubMed: 28910386 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0170445

PubMed: 28118392 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

ACS Omega, 2017, 2(11):7868-7880

PubMed: 30023564 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Anticancer Res, 2017, 37(2):607-614

PubMed: 28179307 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(7):1069-1077

PubMed: 28353145 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

JCI Insight, 2017, 2(3):e89473

PubMed: 28194436 ( click the link to review the publication )
Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94606-94618

PubMed: 29212253 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 9(5):5529-5544

PubMed: 29464016 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28938614 ( click the link to review the publication )

Oncotarget, 2017, 8(61):104193-104205

PubMed: 29262632 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13174-13185

PubMed: 28061458 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29113345 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90037-90049

PubMed: 29163809 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11460-11479

PubMed: 28002790 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Cell, 2017, 168(5):890-903

PubMed: 28162770 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84697-84713

PubMed: 29156677 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )

Melanoma Res, 2017, 27(6):545-557

PubMed: 29076949 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3815-3829

PubMed: 29423085 ( click the link to review the publication )

Oncotarget, 2017, 8(22):36628-36638

PubMed: 28410230 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30151-30161

PubMed: 28404914 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )
Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):349-64

PubMed: 26657862 ( click the link to review the publication )

Nat Commun, 2016, 7:13615

PubMed: 27897178 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2987

PubMed: 27185371 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6021-6030

PubMed: 27259561 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Cancer Res, 2016, 76(3):675-85

PubMed: 26676756 ( click the link to review the publication )

Cancer Res, 2016, 76(20):6095-6106

PubMed: 27569217 ( click the link to review the publication )

Cancer Res, 2016, 76(3):724-35

PubMed: 26637668 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Elife, 2016, 5e12116

PubMed: 26987019 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(12):2475-2484

PubMed: 27498344 ( click the link to review the publication )

Cancers (Basel), 2016,

PubMed: 27187477 ( click the link to review the publication )

J Neurosci, 2016, 36(44):11196-11207

PubMed: 27807163 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2432

PubMed: 27787516 ( click the link to review the publication )

Cell Death Dis, 2016, 7(11):e2456

PubMed: 27809309 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(12):1550-1559

PubMed: 27939899 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1460-71

PubMed: 27196754 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(3):1139-50

PubMed: 26933192 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(12):1204-1216

PubMed: 27655129 ( click the link to review the publication )
Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Mol Cancer Res, 2016,

PubMed: 26582713 ( click the link to review the publication )

Sci Rep, 2016, 6:26803

PubMed: 27222248 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27412232 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Biochemistry, 2016, 10.1172/JCI81468

PubMed: 26974155 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155893

PubMed: 27196001 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

PeerJ, 2016, 4:e1683

PubMed: 26893968 ( click the link to review the publication )

Leuk Res, 2016, 50:1-10

PubMed: 27626202 ( click the link to review the publication )

Methods Enzymol, 2016, 568:557-80

PubMed: 26795484 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26936993 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Integr Biol, 2016, 8(1):73-90

PubMed: 26658688 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7960-9

PubMed: 26799289 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49597-49610

PubMed: 27391062 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19575-88

PubMed: 26988909 ( click the link to review the publication )
Mol Cancer Ther, 2016, 15(1):172-83

PubMed: 26487278 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9102-17

PubMed: 26802022 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30907-23

PubMed: 27127178 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27150057 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78396-78411

PubMed: 27623078 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13886-901

PubMed: 26883104 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.30

PubMed: 25753158 ( click the link to review the publication )

Nat Commun, 2015, 6:8583

PubMed: 26456302 ( click the link to review the publication )

Nat Commun, 2015, 6:7769

PubMed: 26183061 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0013

PubMed: 26034127 ( click the link to review the publication )

Leukemia, 2015, 29(3):705-14

PubMed: 25102946 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(32):9990-5

PubMed: 26216950 ( click the link to review the publication )

Neuro Oncol, 2015, 10.1093/neuonc/nou369

PubMed: 25712957 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )
Oncogene, 2015, 10.1038/onc.2015.97

PubMed: 25867065 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cancer Lett, 2015, 364(1):70-8

PubMed: 25937299 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2015, 28(5):572-89

PubMed: 26112748 ( click the link to review the publication )

J Neurosci, 2015, 35(3):972-84

PubMed: 25609615 ( click the link to review the publication )

J Neurosci, 2015, 35(7):3034-47

PubMed: 25698741 ( click the link to review the publication )

FASEB J, 2015, 10.1096/fj.14-267278

PubMed: 25857555 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1434-46

PubMed: 25933688 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

J Cancer, 2015, 6(12):1195-205

PubMed: 26535060 ( click the link to review the publication )

Gynecol Oncol, 2015, 139(1):118-26

PubMed: 26232337 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Front Oncol, 2015, 5:135

PubMed: 26137449 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Transl Med, 2015, 13:210

PubMed: 26139106 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2014.12.007

PubMed: 25624003 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2015, 308(10):E899-911

PubMed: 25805192 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Biochem J, 2015, 465(2):227-38

PubMed: 25353634 ( click the link to review the publication )

Respir Res, 2015, 16:48

PubMed: 25890309 ( click the link to review the publication )

Int J Oncol, 2015, 47(3):849-56

PubMed: 26179332 ( click the link to review the publication )
Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Exp Cell Res, 2015, 332(1):1-10

PubMed: 25637219 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Radiat Oncol, 2015, 10:214

PubMed: 26498922 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 456(3):821-6

PubMed: 25498501 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015, 6(5):3165-77

PubMed: 25638158 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17491-500

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(16):14472-87

PubMed: 25961376 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33397-409

PubMed: 26397223 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26544513 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(9):1104-18

PubMed: 26105199 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8698-708

PubMed: 25826088 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26317790 ( click the link to review the publication )
J Invest Dermatol, 2015, 135(7):1863-1872

PubMed: 25789707 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Blood, 2014, 27;124(23):3420-30

PubMed: 25253770 ( click the link to review the publication )

Nat Commun, 2014, 5:3901

PubMed: 24849047 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(8):5083-96

PubMed: 24526220 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(23):6023-33

PubMed: 25316819 ( click the link to review the publication )

Leukemia, 2014, 10.1038/leu.2014.187.

PubMed: 24912431 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2825-34

PubMed: 24648348 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Oncogene, 2014, 33(33):4236-41

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.392

PubMed: 25435367 ( click the link to review the publication )

J Invest Dermatol, 2014, 134(2):366-73

PubMed: 23924903 ( click the link to review the publication )

Sci Signal, 2014, 7(357):ra122

PubMed: 25538080 ( click the link to review the publication )

Sci Signal, 2014, 7(311):ra12

PubMed: 24497609 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(3):479-84

PubMed: 24422853 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

FASEB J, 2014, 10.1096/fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(2):353-63

PubMed: 24398428 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(7):1894-906

PubMed: 24825855 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0452

PubMed: 25349308 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(2):161-73

PubMed: 24243688 ( click the link to review the publication )
Mol Nutr Food Res, 2014, 58(3):528-36

PubMed: 24039193 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Hum Mol Genet, 2014, 23(1):1-11

PubMed: 23933734 ( click the link to review the publication )

Mol Cancer Res, 2014, 12(10):1509-19

PubMed: 24962318 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4088-103

PubMed: 25182533 ( click the link to review the publication )

Neuroscience, 2014, 562:69-74

PubMed: 24412130 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Exp Cell Res, 2014, 327(2):340-52

PubMed: 25128814 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 73(2):259-70

PubMed: 24253175 ( click the link to review the publication )

PLoS One, 2014, 9(2):e83957

PubMed: 24551032 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115068

PubMed: 25500581 ( click the link to review the publication )

PLoS One, 2014, 9(10):e110306

PubMed: 25330306 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97938

PubMed: 24835245 ( click the link to review the publication )

PLoS One, 2014, 9(2):e89646

PubMed: 24586933 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(4):958-61

PubMed: 25218145 ( click the link to review the publication )

Radiat Res, 2014, 182(3):350-62

PubMed: 25117621 ( click the link to review the publication )

Sensors (Basel), 2014, 14(3):5074-117

PubMed: 24625737 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 24962990 ( click the link to review the publication )

Mol Cancer, 2014, 13:154

PubMed: 24941944 ( click the link to review the publication )
Tumor Biol, 2014, 35(10):9759-67

PubMed: 24972969 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10732-44

PubMed: 25313141 ( click the link to review the publication )

Blood, 2013, 121(23):4617-26

PubMed: 23575444 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

Hepatology, 2013, 59(4):1435-47

PubMed: 24242874 ( click the link to review the publication )

J Clin Invest, 2013, 124(1):156-68

PubMed: 24316974 ( click the link to review the publication )

J Clin Invest, 2013, 123(6):2551-63

PubMed: 23635776 ( click the link to review the publication )

J Clin Invest, 2013, 123(5):2155-68

PubMed: 23543055 ( click the link to review the publication )

J Natl Cancer Inst, 2013, 105(1):33-46

PubMed: 23250956 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(1):118-27

PubMed: 23091117 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 10.1038/onc.2013.389

PubMed: 24096476 ( click the link to review the publication )

Cancer Res, 2013, 73(23):7101-10

PubMed: 24121492 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Mol Syst Biol, 2013,

PubMed: 23752269 ( click the link to review the publication )

Cell Rep, 2013, 4(6):1090-9

PubMed: 24055054 ( click the link to review the publication )

Oncogene, 2013, 33(33):4236-41

PubMed: 24336323 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013, 5(206):ra3

PubMed: 22234612 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):509-17

PubMed: 23490205 ( click the link to review the publication )
J Neurosci, 2013, 33(10):4280-94

PubMed: 23467345 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

Cancer Discov, 2013, 3(4):444-57

PubMed: 23358651 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(6):1131-9

PubMed: 23515613 ( click the link to review the publication )

J Mol Cell Cardiol, 2013, 59:139-47

PubMed: 23510923 ( click the link to review the publication )

Carcinogenesis, 2013, 34(3):638-46

PubMed: 23172668 ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Skelet Muscle, 2013, 3(1):17

PubMed: 23815988 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(20):4051-67

PubMed: 23959801 ( click the link to review the publication )

Exp Cell Res, 2013, 319(12):1732-43

PubMed: 23701950 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

Oncol Rep, 2013, 29(2):812-8

PubMed: 23229346 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 500(7461):222-6

PubMed: 24349570 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68817

PubMed: 23935891 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )

Oncotarget, 2013, 4(9):1496-506

PubMed: 24036604 ( click the link to review the publication )

University of Southampton, 2013, University of Southampton

PubMed: ( click the link to review the publication )

Nature, 2013, 504(7478):138-42

PubMed: 24185007 ( click the link to review the publication )

Cancer Res, 2013, 73(15):4840-51

PubMed: 23737487 ( click the link to review the publication )

Gut, 2012, 61(2):202-13

PubMed: 21813469 ( click the link to review the publication )

J Clin Invest, 2012, 122(7):2637-51

PubMed: 22653055 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )
Oncogene, 2012, 31(27):3277-86

PubMed: 22020336 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

Cardiovasc Res, 2012, 93(2):311-9

PubMed: 22068161 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(2):317-28

PubMed: 22188813 ( click the link to review the publication )

Endocr Relat Cancer, 2012, 19(1):29-38

PubMed: 22109971 ( click the link to review the publication )

Carcinogenesis, 2012, 33(5):956-61

PubMed: 22327936 ( click the link to review the publication )

Am J Pathol, 2012, 180(6):2462-78

PubMed: 22546478 ( click the link to review the publication )

J Biol Chem, 2012, 287(50):41797-807

PubMed: 23076151 ( click the link to review the publication )

Surgery, 2012, 152(6):1142-9

PubMed: 23158184 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2012, 304(5):C431-9

PubMed: 23255578 ( click the link to review the publication )

Neuroscience, 2012, 206:224-36

PubMed: 22280975 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(1):43-9

PubMed: 22336587 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29622

PubMed: 22253748 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

Aging, 2012, 4(11):803-822

PubMed: 23362510 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Biomaterials, 2011, 32(35):9197-206

PubMed: 21899882 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:489

PubMed: 21613978 ( click the link to review the publication )

J Invest Dermatol, 2011, 132(2):356-64

PubMed: 21993556 ( click the link to review the publication )

J Clin Endocrinol Metab, 2011, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cancer Res, 2011, 9(5):545-52

PubMed: 21478267 ( click the link to review the publication )
Endocrinology, 2011, 152(7):2589-98

PubMed: 21521747 ( click the link to review the publication )

Mol Endocrinol, 2011, 25(12):2041-53

PubMed: 22053001 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

Biol Reprod, 2011, 85(1):42-50

PubMed: 21349822 ( click the link to review the publication )

PLoS One, 2011, 6(12):e28973

PubMed: 22194965 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Brit J Haematol, 2010, 149(4):537-49

PubMed: 20331454 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Nature, 2010, 468(7326):973-7

PubMed: 21107323 ( click the link to review the publication )

P Natl Acad Sci USA, 2009, 106(48):20411-6

PubMed: 19915144 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

First MEK inhibitor being tested in Phase II clinical trials.

Targets

MEK1 ^[1] (Cell-free assay)	MEK1 ^[13] (Cell-free assay)	MEK2 ^[13] (Cell-free assay)
14 nM	99 nM(Kd)	530 nM(Kd)

In vitro

AZD6244 is not competitive with ATP and inactivates the ERK1/2 phosphorylation with IC50 concentrations below 40 nM. AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90^RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. AZD6244 has little effects on the p38, c-Jun-NH₂-kinase, phosphatidylinositol 3-kinase, and MEK5/ERK5 pathways. ^[1] AZD6244 is sensitive to Raf mutations in breast cancer cell lines and Ras mutations in NSCLC cell lines. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
CHP-212	NVjUTpkyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODB\|MUWzJO69VS5?	NEn5UXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H9	M2q0SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXfOUndvUW6qaXLpeIlwdiCxZjDoeY1idiCKOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xOjJ6ODFOwG0v	M175XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HL-60	M4GzOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWHVXodbUW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yMkS1PUDPxE1w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NOMO-1	MnXVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkLpTY5pcWKrdHnvckBw\iCqdX3hckBPV02RLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvODNzOUeg{txONg>?	M3zNXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DU-4475	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4LoWmlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yM{O2O{DPxE1w	NY\IUHVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
M14	Mo\XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWLJcohq[mm2aX;uJI9nKGi3bXHuJG0yPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wN\|Y5QSEQvF2u	M2LaRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HT-144	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhVNTF2NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xQDlyNTFOwG0v	NEn2Z3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-N-AS	NEnEOIdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M17jSGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3BV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yOUK4N{DPxE1w	NGT4W5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LB2518-MEL	M2\iUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHjidYlKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkWxPE1OTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNFk{QDJizszNMi=>	M3;GSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
C32	MljNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH\BU\|NKdmirYnn0bY9vKG:oIHj1cYFvKEN\|MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xQTh{MzFOwG0v	M{HjW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BHT-101	NHvybVFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mo\ITY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjFyNkmzJO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KY821	MnjWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnLsTY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yODdzODFOwG0v	M4HFblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CP50-MEL-B	NVz4N45KT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYnJVXF5UW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlEzPzl2IN88UU4>	NF\5Tnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MEL-HO	NGHzVYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXTJcohq[mm2aX;uJI9nKGi3bXHuJG1GVC2KTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yOzh6NDFOwG0v	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EoL-1-cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml:1TY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkG0OFc3KM7:TT6=	NUX0OWtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DOK	NU\Jb2h[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlLvTY5pcWKrdHnvckBw\iCqdX3hckBFV0tiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNVQ4ODhizszNMi=>	NWXid2tLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SH-4	M1S3eGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNJNTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IECuNVY3PDhizszNMi=>	Mmj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BPH-1	NFSyV\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn[xTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4yQDJ\|MTFOwG0v	NFHWZmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HuP-T4	M1rQS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFzoT21KdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5zOUWzNkDPxE1w	NV;kOoE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KU812	NXLCWmJXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWjZb4dJUW6qaXLpeIlwdiCxZjDoeY1idiCNVUixNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{MUG2PEDPxE1w	NGrqeIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A549	M1T6[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2fP[WlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zOTRzMzFOwG0v	M4\SPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HTC-C3	Mn;6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3T5UWlvcGmkaYTpc44hd2ZiaIXtZY4hUFSFLVOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJzNE[xJO69VS5?	NVTseW9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A101D	M{DacWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkH5TY5pcWKrdHnvckBw\iCqdX3hckBCOTBzRDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4zPDB\|MzFOwG0v	MlXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ONS-76	NYTXcWFZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFjDVXBKdmirYnn0bY9vKG:oIHj1cYFvKE:QUz23OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{NES1N{DPxE1w	NHLScmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RKO	NWjLcFdoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX63O4t1UW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOjR6M{ig{txONg>?	NVO3d\|JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
WM-115	NUD3RZJzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEHrWHhKdmirYnn0bY9vKG:oIHj1cYFvKFePLUGxOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{Nke1OEDPxE1w	NW\FOI9yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC2998	M13Remdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWTpbXN4UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyPVk5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLkK2PVA4KM7:TT6=	Ml[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
C2BBe1	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGK3TJFKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{N{K1PUDPxE1w	MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RVH-421	NYXKd5JCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3O0XWlvcGmkaYTpc44hd2ZiaIXtZY4hWl[KLUSyNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5{N{mzPUDPxE1w	NXPDdm94RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
H-EMC-SS	NHzaeFRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1z4Z2lvcGmkaYTpc44hd2ZiaIXtZY4hUC2HTVOtV3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMkmwPVkh\|ryPLh?=	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ML-2	M1vFWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUK3eWNjUW6qaXLpeIlwdiCxZjDoeY1idiCPTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjJ7M{[zJO69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW620	M3;6WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlnZTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4{ODJ{IN88UU4>	MlzpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
UACC-257	NV\DR3lVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnW1TY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5\|MkG4OEDPxE1w	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
AsPC-1	NYLKNYh[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2TNUWlvcGmkaYTpc44hd2ZiaIXtZY4hSXOSQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN{NEO5JO69VS5?	M1fY[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-39	MnXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1\|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4{OzJ{NjFOwG0v	NXrrNFk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-679	MkTkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4n4XmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O\|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwM{SxNVkh\|ryPLh?=	NF7PXZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H747	M1HURWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUXxWZVGUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFc1PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6zOVA6QCEQvF2u	NHXDPGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1437	MoO4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGjyNGVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVQ{PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6zOVI5PSEQvF2u	MnzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
PSN1	M3jacmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEjYXmFKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzZ4MEmg{txONg>?	NFvSVnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NKM-1	NIX5O2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2DsUWlvcGmkaYTpc44hd2ZiaIXtZY4hVkuPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvOzh3ODFOwG0v	MkK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MZ2-MEL	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlnSTY5pcWKrdHnvckBw\iCqdX3hckBOYjJvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjN7NEO3JO69VS5?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-MEL-2	MnPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXvJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjRyNUC2JO69VS5?	MmnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LAMA-84	MoKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFPQ[nVKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwNEW2NlIh\|ryPLh?=	NFTrVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
U-266	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mlj5TY5pcWKrdHnvckBw\iCqdX3hckBWNTJ4NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE41QDd5NDFOwG0v	NVjrcGtWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RCM-1	M3PkPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWDJcohq[mm2aX;uJI9nKGi3bXHuJHJEVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlQ6Ozh3IN88UU4>	MoPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EM-2	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jTUmlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42OTF5NTFOwG0v	NGfuV4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Mewo	MkC0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M16zWGlvcGmkaYTpc44hd2ZiaIXtZY4hVWW5bzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42OjFyMTFOwG0v	NE\nNXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
COLO-741	M33RUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vN{SxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjV\|MUG5JO69VS5?	NFPC[4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ACN	NELtdW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M160Z2lvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlU3PjlizszNMi=>	MnnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MV-4-11	NFXPTWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPTd3NEOg{txONg>?	MoXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW780	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkLTTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE43PjZ\|NDFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
JVM-3	M{CyN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXLJcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlcxODZizszNMi=>	NUnjcZhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RPMI-8226	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3\PbmlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke0JO69VS5?	NEnwTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HO-1-N-1	NGTJcINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAxNjd2MEWyJO69VS5?	M3PJXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BV-173	MlK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkTGTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvPzR6MEKg{txONg>?	M{jtOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2291	M2ryb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2TIdWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlkyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLke2NVc{KM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-MEL-30	M2TPSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkjsTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN\|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{ixO\|Eh\|ryPLh?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LB2241-RCC	Mn\YS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3vZ[mlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD63PFk6OSEQvF2u	MmTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
LOXIMVI	M4rBc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXLSNoNzUW6qaXLpeIlwdiCxZjDoeY1idiCOT2jJUXZKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSByLki1PFU1KM7:TT6=	NGL3SI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HT-29	Mnr5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M37YZmlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQDd\|MUmg{txONg>?	M3fj[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KG-1	NXvYPYR1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NICzXG9KdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQDl3NEeg{txONg>?	NIXMNm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW954	NXvpNFFoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1jieGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFAvQDl4NEWg{txONg>?	M3fiXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MIA-PaCa-2	NFfOZWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwOEm3Olgh\|ryPLh?=	MknGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCE-T	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVfBXJh5UW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC57N{GzNUDPxE1w	NGq2NWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HN	NH7oVlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NV\kRno6UW6qaXLpeIlwdiCxZjDoeY1idiCKTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4xODJ3NzFOwG0v	NFraPYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LCLC-97TM1	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NI\ISJJKdmirYnn0bY9vKG:oIHj1cYFvKEyFTFOtPVdVVTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNFMyQTFizszNMi=>	NF:xRXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NB69	M{\4U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1vvNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4xPTN7IN88UU4>	NHjVTm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LoVo	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUjGcnRtUW6qaXLpeIlwdiCxZjDoeY1idiCOb2\vJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjB4MkOxJO69VS5?	M1\KUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HCT-116	NYjxWIhZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mom0TY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjB4NEOxJO69VS5?	Mo\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
AGS	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnfZTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNVE5OzFizszNMi=>	NX[0fFJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H292	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjFzOUmg{txONg>?	NUHn[pRxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
P12-ICHIKAWA	MljVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3LxVmlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlE2QDl7IN88UU4>	NHPXNYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
D-263MG	Ml;6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXnJcohq[mm2aX;uJI9nKGi3bXHuJGQuOjZ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOThyOUSg{txONg>?	Mn:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
COLO-792	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mk\oTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5zOE[zJO69VS5?	NXq1S5ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HSC-3	NX3jPIxxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1XoWWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOTh6MkOg{txONg>?	NFrNO\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NUGC-3	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUG5eJU1UW6qaXLpeIlwdiCxZjDoeY1idiCQVVfDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwMkCzO\|kh\|ryPLh?=	NEn2WY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW872	M1zXWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3;KVmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvOjZ6NUWg{txONg>?	NITZRYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HuCCT1	Ml3kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFLJcVhKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS5{OUm2JO69VS5?	NIXpcVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
QIMR-WIL	NVX4d24{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUjJcohq[mm2aX;uJI9nKGi3bXHuJHFKVVJvV1nMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjN2M{i0JO69VS5?	M4\JS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2087	NGjJflNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUi1cot1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuN\|c2OSEQvF2u	NEXBRlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LS-513	NFPlRpJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkTUTY5pcWKrdHnvckBw\iCqdX3hckBNWy13MUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPDJzOUGg{txONg>?	NWLxRot[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CAL-54	NVL4OFhYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mle5TY5pcWKrdHnvckBw\iCqdX3hckBESUxvNUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPDl\|MUSg{txONg>?	NEfSdpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
A204	NInTZYZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlX5TY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlUyPjZ5IN88UU4>	M4nMNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-62	Mn;iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU42OjJ7MjFOwG0v	NGftTGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-33	NFvScW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU42PDZ7NDFOwG0v	NVr0Z4tMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-678	MlGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{HxSWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O\|gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNkKzPFIh\|ryPLh?=	M4TkcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MEG-01	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlfjTY5pcWKrdHnvckBw\iCqdX3hckBOTUdvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPjJ7NUmg{txONg>?	NGLzcIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HAL-01	M4f3Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWPobGV5UW6qaXLpeIlwdiCxZjDoeY1idiCKQVytNFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwNkm1O{DPxE1w	NEXzd3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OAW-28	NHnmNZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3PHN2lvcGmkaYTpc44hd2ZiaIXtZY4hV0GZLUK4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyNjd2M{m3JO69VS5?	M3rQWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-SNU-1	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MULJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS55N{K0N{DPxE1w	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BHY	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGJJYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT64NVA{PCEQvF2u	NUHaVGVjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EGI-1	NYXFOZQxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPlW45HUW6qaXLpeIlwdiCxZjDoeY1idiCHR1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS56MkiyJO69VS5?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
BB65-RCC	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVjqR2p3UW6qaXLpeIlwdiCxZjDoeY1idiCEQk[1MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMT64N\|g2PSEQvF2u	M3X6VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GAK	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml:wTY5pcWKrdHnvckBw\iCqdX3hckBISUtiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuPVA1PzVizszNMi=>	NILsW2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-MEL-3	NX74UFVVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4DzPWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFwOUWwO\|ch\|ryPLh?=	NYC1OJVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KARPAS-45	NGPyW3lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGtCWlCDUz20OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi5yOEK0PEDPxE1w	NH3BXnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BCPAP	NGLMZZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVPJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlEzPzRizszNMi=>	Ml;yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RT-112	MmTOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXXJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk4zPjB2NjFOwG0v	NGj4cFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-HEP-1	MlryS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M33tbmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvSFXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwMkmwOFgh\|ryPLh?=	M3PJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
Ca9-22	M4fTXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFPONlhKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi5\|N{[2O{DPxE1w	M1zL[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
OS-RC-2	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{ezdWlvcGmkaYTpc44hd2ZiaIXtZY4hV1NvUlOtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi52MEOzO{DPxE1w	NX\xdZhQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BFTC-905	NITZbYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXm2VFVGUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMj60NlMyOiEQvF2u	NFz4SVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HT-1080	M13KVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFPjVWNKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwNEOwNUDPxE1w	MmjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC2218	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NG[5OIFKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{KyNVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwNEi0PFch\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KM12	M4rDcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn;oTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlU{QTZzIN88UU4>	NVrxbYExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NB5	Ml3MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3LO[mlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlU3PjRzIN88UU4>	M2KxUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BB30-HNC	MoKwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjdzMkmzJO69VS5?	NUnCS\|JDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H460	NUizZm01T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3Lw[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwOECyO\|Qh\|ryPLh?=	NGG0SoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LAN-6	NEi4TYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVPJS2lWUW6qaXLpeIlwdiCxZjDoeY1idiCOQV6tOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOi56Mki2O{DPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
EW-3	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NEnt[\|JKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvQTJ3MEWg{txONg>?	M4S1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
CAL-27	NGLYfWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYnkOYZYUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwME[xNVgh\|ryPLh?=	NFfJUVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
COR-L105	NXrpTXNwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUPQXopsUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFExPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMz6xN\|Q3OiEQvF2u	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EFO-21	NXPFUpNyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1\3VmlvcGmkaYTpc44hd2ZiaIXtZY4hTU[RLUKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjF7MkK2JO69VS5?	NILadWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
MZ1-PC	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{4{OTZyNTFOwG0v	MkO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EFO-27	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUfNZlBGUW6qaXLpeIlwdiCxZjDoeY1idiCHRl:tNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwM{K2NVIh\|ryPLh?=	M4HS[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HPAF-II	NV;rN\|JPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVO1TXpRUW6qaXLpeIlwdiCxZjDoeY1idiCKUFHGMWlKKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|LkOzO\|I6KM7:TT6=	NF7SNYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KU-19-19	Ml3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2nSVGlvcGmkaYTpc44hd2ZiaIXtZY4hU1VvMUmtNVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwNEG5OVEh\|ryPLh?=	NWjCeJFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-SNU-5	M2X2PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFfJXY9KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMz62NVQ1QSEQvF2u	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LS-123	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NELy[IVKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUGyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy54MUizNUDPxE1w	NYLT[ldnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
769-P	NH73W5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn;5TY5pcWKrdHnvckBw\iCqdX3hckA4PjlvUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{44PDJ4IN88UU4>	M3y2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SJSA-1	NES5XGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNLW0FvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{44QDF2NjFOwG0v	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-LU-1	M3HTeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4jmc2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTGWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy56NkKzNUDPxE1w	M3;3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A3-KAW	MoXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3LiWWlvcGmkaYTpc44hd2ZiaIXtZY4hSTNvS1HXJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{NjlzMEW1JO69VS5?	M2HMbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
LB996-RCC	NEHuXmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXjDVJE5UW6qaXLpeIlwdiCxZjDoeY1idiCOQkm5Ok1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOuPVUxPDNizszNMi=>	M3fublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SN12C	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NELFUW9KdmirYnn0bY9vKG:oIHj1cYFvKFOQMULDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Njl3NUezJO69VS5?	M2rDb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
COR-L23	NULiUlRZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWrwT\|ZkUW6qaXLpeIlwdiCxZjDoeY1idiCFT2KtUFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Lkm1OlY6KM7:TT6=	NV3ETWFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
VM-CUB-1	M1PseGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlfPTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy57NkmzNUDPxE1w	NGPjWnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RXF393	MmWwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWfhUYVpUW6qaXLpeIlwdiCxZjDoeY1idiCUWF[zPVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMEG1PVEh\|ryPLh?=	NVm3OYoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MOLT-13	NFr4UFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXm4UHFLUW6qaXLpeIlwdiCxZjDoeY1idiCPT1zUMVE{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2LkCzOFE6KM7:TT6=	NH3DWWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GCT	MlTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2fDZ2lvcGmkaYTpc44hd2ZiaIXtZY4hT0OWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0MlExPDR{IN88UU4>	M336XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW1990	NFXUUGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTl7MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4yPjZ{MjFOwG0v	NFzyO3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RD	M{LsfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV;2PJZ3UW6qaXLpeIlwdiCxZjDoeY1idiCURDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4yQTF\|ODFOwG0v	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HOP-92	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGhQWC17MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4zODB7MzFOwG0v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ME-180	Ml[xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEfFVY1KdmirYnn0bY9vKG:oIHj1cYFvKE2HLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5{NUi1PUDPxE1w	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MZ7-mel	NYTwT2tvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUfTeWFMUW6qaXLpeIlwdiCxZjDoeY1idiCPWketcYVtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2LkS1NlY2KM7:TT6=	NHrZVZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAKI-1	NW\UVVV5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmfuTY5pcWKrdHnvckBw\iCqdX3hckBESUuLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPDZyNUeg{txONg>?	MkLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
YKG-1	NFzvW2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXzJcohq[mm2aX;uJI9nKGi3bXHuJHlMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0MlU{PDJzIN88UU4>	NULHeJNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
PANC-03-27	NFn1[GlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NETTTItKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuOVM6OjlizszNMi=>	M1HvfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A4-Fuk	MljlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mmi3TY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPTR{MEKg{txONg>?	NUfqT5JvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H441	M1TBcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWGzOGdnUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ1OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iND61OlM1OiEQvF2u	NWLSTpVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BxPC-3	M4ruTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYrmcnE2UW6qaXLpeIlwdiCxZjDoeY1idiCEeGDDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwNkW5O\|Yh\|ryPLh?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
ES3	MoL1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYrMWFVwUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPjlzN{Og{txONg>?	NEfLNWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GP5d	NF:4W2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGdRPWRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuO\|g2PTNizszNMi=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CAL-85-1	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGLu[otKdmirYnn0bY9vKG:oIHj1cYFvKEODTD24OU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Lke5OFIh\|ryPLh?=	NGrSepg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
EPLC-272H	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUnLV5JmUW6qaXLpeIlwdiCxZjDoeY1idiCHUFzDMVI4OkhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuPFE3QThizszNMi=>	NXXUUlJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HuP-T3	NILI[GJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUnJcohq[mm2aX;uJI9nKGi3bXHuJGh2WC2WMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE45OjRyODFOwG0v	NYDMUJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1710	NYTmRXVKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnTjTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvODN3NEmg{txONg>?	MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-8	NWXKO5ZIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIXjR5hKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvODZ7MUGg{txONg>?	M1nNTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-12	NV36eGVLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mom4TY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOU4yOzdyMzFOwG0v	NXPENG9MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1573	Mny0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4LZZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOVc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3LkK3NlM5KM7:TT6=	NXXDOnhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SW1417	NGfnTFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVX0bZBCUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G0NVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwMkezPVgh\|ryPLh?=	NYrIUlJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
CHL-1	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGnQbYhKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjNzOUmg{txONg>?	NXTWfGQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
Calu-6	NE\H[WRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmC0TY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3LU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvPDJ7Mkeg{txONg>?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MDA-MB-231	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn6yTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3LkW2OVI{KM7:TT6=	M3HPbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SCC-25	NUPPeph4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlTWTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvMkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvQTdzMkGg{txONg>?	NID6Z4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
639-V	NWDJNm12T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{DBdmlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFYvOTJ7M{Og{txONg>?	MoCwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
D-502MG	MkflS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1vUTGlvcGmkaYTpc44hd2ZiaIXtZY4hTC13MELNS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi5zN{[1PUDPxE1w	M3fYclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
PANC-10-05	M1[4fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVjublc2UW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVExNTB3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlIxOThzIN88UU4>	MkK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	MmTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGTs[JhKdmirYnn0bY9vKG:oIHj1cYFvKFKjbX;zMVJIPi12Q{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjJ5MEm0JO69VS5?	NFnvOnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NB10	NFnoR4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mly5TY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC2MlMzPTN\|IN88UU4>	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MSTO-211H	NUK1W5FKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJG1UXE9vMkGxTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi52MEC4JO69VS5?	NE\ITZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H1651	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXz6WoR[UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE3PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uOlU{OjhizszNMi=>	MoS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
697	NU\SPYw{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNj62O\|M6PyEQvF2u	NVXBPYhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC70	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mk\DTY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOk43QDh4NTFOwG0v	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SW1116	NFzaSINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoC5TY5pcWKrdHnvckBw\iCqdX3hckBUXzFzMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFYvQDF{OUeg{txONg>?	NInNR5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SK-MES-1	NH\VbGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml25TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi56NEi4JO69VS5?	NUHBN4ptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
GCIY	NXmxOoo{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IE[uPVE6PjJizszNMi=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
GMS-10	NF\LW\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVrJcohq[mm2aX;uJI9nKGi3bXHuJGdOWy1zMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{4xPzd3NTFOwG0v	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1092	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHTzNVJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVA6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNz6xOVM{PCEQvF2u	NFrmWoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CFPAC-1	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1X2dmlvcGmkaYTpc44hd2ZiaIXtZY4hS0[SQVOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy5{MkGwNUDPxE1w	Mlz3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TK10	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXrjV3M{UW6qaXLpeIlwdiCxZjDoeY1idiCWS{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjN3NUi3JO69VS5?	M3joeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
FADU	Mo\kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGZCTFViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEeuOVA6OyEQvF2u	M1e5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
8305C	Mn34S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlLWTY5pcWKrdHnvckBw\iCqdX3hckA5OzB3QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{45PTN3NTFOwG0v	Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
DK-MG	M2HVXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVnJcohq[mm2aX;uJI9nKGi3bXHuJGRMNU2JIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC3Mlk1QTN5IN88UU4>	NWHwWHlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
BFTC-909	M37wWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1jUWGlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwOUe4N\|Yh\|ryPLh?=	NFHreoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
IGR-1	MlfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXnJcohq[mm2aX;uJI9nKGi3bXHuJGlIWi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlE5ODVzIN88UU4>	NYDhTWdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MDA-MB-361	NHjre\|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml\NTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN\|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB6LkG4NlQh\|ryPLh?=	MkTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KYSE-150	MmiyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnzrTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG1NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQC5{MUmzO{DPxE1w	M2iyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
DB	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2jje2lvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEiuN\|Y6ODVizszNMi=>	NGnzSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NH-12	MkTNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHTPUmJKdmirYnn0bY9vKG:oIHj1cYFvKE6KLUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjR{N{O2JO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
CTV-1	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3;wVWlvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvPDN\|M{eg{txONg>?	MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A498	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmLuTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4Mlc5PDd3IN88UU4>	NHvJWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LS-1034	NX:1RolTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGxUNTFyM{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvQTZ2NkSg{txONg>?	NYfKem9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
FTC-133	Mn74S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGZVSy1zM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvQTh2NUmg{txONg>?	MnKwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TGBC11TKB	NGPrW2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmDjTY5pcWKrdHnvckBw\iCqdX3hckBVT0KFMUHUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDlwMUC4N\|Yh\|ryPLh?=	M1LSRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-MEL-1	M4C4V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoiwTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS5zOUGzOkDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RPMI-7951	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYXqe3B7UW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuNlUzODFizszNMi=>	MnPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
GT3TKB	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUXJNZBRUW6qaXLpeIlwdiCxZjDoeY1idiCJVEPUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDlwM{e0NFMh\|ryPLh?=	MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SW962	NG\sNppIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M131RWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFkvPTJ\|MkWg{txONg>?	MmPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
T-24	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2LvSGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU43PThyNzFOwG0v	NFn6OmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	NXvIdXN2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGDucIhKdmirYnn0bY9vKG:oIHj1cYFvKESEVGLHMVA2VUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEmuO\|U3PjZizszNMi=>	NV6xeIhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
G-401	NXPFPY44T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNE4xPzN7IN88UU4>	NYrpXmg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
RS4-11	NXiyTVZQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXmyU4NyUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkK3PVEh\|ryPLh?=	NHTzT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KGN	MkD0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEjtZWRKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPDB2NjFOwG0v	MnHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
786-0	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3;MWmlvcGmkaYTpc44hd2ZiaIXtZY4hPzh4LUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjRzNk[g{txONg>?	Mk\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
EW-18	M37xdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXzyeXNMUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTBwNEO2OkDPxE1w	NHrJVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
DEL	NFflOoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlTxTY5pcWKrdHnvckBw\iCqdX3hckBFTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGwMlU1PSEQvF2u	Mn\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HuH-7	NFPrXFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGnrUZBKdmirYnn0bY9vKG:oIHj1cYFvKEi3SD23JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOC53N{C1JO69VS5?	MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MG-63	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnT5TY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPzN\|MzFOwG0v	M3HSe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
A253	NFj4fWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M32wSmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ3MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPzlyMjFOwG0v	MljIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TGW	MmrKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEjKXFBKdmirYnn0bY9vKG:oIHj1cYFvKFSJVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPzl\|NzFOwG0v	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HH	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX\jZlI4UW6qaXLpeIlwdiCxZjDoeY1idiCKSDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvQDB4MjFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
LS-411N	NGS0UFNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJGxUNTRzMV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjh{NESg{txONg>?	NXSyWGNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H2347	NH25VZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4jDWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN\|Q4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD64OFM4KM7:TT6=	NXzFVIl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
LU-65	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkDNTY5pcWKrdHnvckBw\iCqdX3hckBNXS14NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvQTJ{NjFOwG0v	M1TkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-11	M3u3cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXPmNXgyUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwMEK1JO69VS5?	MnHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SBC-1	M{XZRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnj0TY5pcWKrdHnvckBw\iCqdX3hckBUSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvOTB\|MjFOwG0v	NXi4RVZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
TGBC24TKB	NYXUNIZnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3\GWmlvcGmkaYTpc44hd2ZiaIXtZY4hXEeEQ{K0WGtDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMT6xNVgh\|ryPLh?=	MoP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
ECC10	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M125fmlvcGmkaYTpc44hd2ZiaIXtZY4hTUOFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjJ{OEOg{txONg>?	NITNS5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GR-ST	NHHJPHZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1LYN2lvcGmkaYTpc44hd2ZiaIXtZY4hT1JvU2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjJ4ODFOwG0v	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H720	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{KwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS5\|OUe3JO69VS5?	M3jFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
VA-ES-BJ	M2nUZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYLJcohq[mm2aX;uJI9nKGi3bXHuJHZCNUWVLVLKJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS53NUGzJO69VS5?	NV3Td2VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MOLT-16	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGjacZhKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkGxOlEh\|ryPLh?=	NELxWGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KYSE-140	NVrCe\|FrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMUSwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi5zNUm2JO69VS5?	NUjPVHo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SCC-4	NHjH[JFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF7uSHpKdmirYnn0bY9vKG:oIHj1cYFvKFOFQz20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi5{NDFOwG0v	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1155	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYHsN5JXUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEyPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGyMlMxOTdizszNMi=>	NVe3OpBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
OCUB-M	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVv4eG4xUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkOxPFkh\|ryPLh?=	NUjxbpBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MN-60	NWrhfJU4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHe3d\|JKdmirYnn0bY9vKG:oIHj1cYFvKE2QLU[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOi5\|N{OyJO69VS5?	NHztd5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RO82-W-1	M1TGfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NYrLWnB7UW6qaXLpeIlwdiCxZjDoeY1idiCUT{iyMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuN\|g4QSEQvF2u	NU\5e5N[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KOSC-2	M{K3Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlvRTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjV3MEig{txONg>?	MmfWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
L-363	Mk\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmfYTY5pcWKrdHnvckBw\iCqdX3hckBNNTN4MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvPTl{NTFOwG0v	NWPjXmhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H661	NHTrcplIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4PaSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{Lki1PFch\|ryPLh?=	Mnn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KYSE-450	NGnw[WxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHrWb5VKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMz6wN\|k3KM7:TT6=	NEGwfFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
TI-73	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkPOTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVMvODR2IN88UU4>	NXr3VmFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
KNS-81-FD	NEe3Om9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGtPWy16MT3GSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMEe0PEDPxE1w	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HCC1954	Mn63S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE{NjJ5OEOg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
A427	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MofTTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxN{43Pjh7IN88UU4>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MOLT-4	NIXMdGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVMvQDV\|MTFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
U-118-MG	NEDwUYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mln3TY5pcWKrdHnvckBw\iCqdX3hckBWNTFzOD3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwOEewNkDPxE1w	MnO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SF126	NGLBS2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHrFUIxKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy57MU[1JO69VS5?	M4LIb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SF539	MlSyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NESxWnFKdmirYnn0bY9vKG:oIHj1cYFvKFOINUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy57NEe0JO69VS5?	NWDrTWJzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
Daoy	NGXmcnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWTjdnhRUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC52OUe5JO69VS5?	NX\sS5UyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
DoTc2-4510	NHLBTY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGRwXGN{LUS1NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF2LkWxO\|Uh\|ryPLh?=	MmrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TYK-nu	Ml62S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmnpTY5pcWKrdHnvckBw\iCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE1NjV4IN88UU4>	NGHobVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CGTH-W-1	M4H4bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC56NEizJO69VS5?	M3;HVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HuO9	M3nXS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mo\ZTY5pcWKrdHnvckBw\iCqdX3hckBJfU97IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU4xPjNizszNMi=>	NWDV[pZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EW-16	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NW\xbmRTUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTVwMEm0PUDPxE1w	NHTORZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H630	NUnINIRpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFPU[YRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNT6xOlE{KM7:TT6=	NHLpRXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
CAL-12T	M1fLeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NILQV3pKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF3LkOzNUDPxE1w	MlfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
TE-5	M4nM[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIXRUFRKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE2NjZzM{Og{txONg>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
U251	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmjlTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU44Ozh\|IN88UU4>	M36xdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
BB49-HNC	M13oOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFnWZXdKdmirYnn0bY9vKG:oIHj1cYFvKEKENEmtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNj61NFYh\|ryPLh?=	NEHYOFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OCI-AML2	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHK2Z3JKdmirYnn0bY9vKG:oIHj1cYFvKE:FST3BUWwzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNj62OlUh\|ryPLh?=	MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KINGS-1	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGtKVkeVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE3NjZ7MUig{txONg>?	NWXGeWl[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
D-566MG	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTZ4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE3Njd{NkKg{txONg>?	M37qTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
P30-OHK	Mlz2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn70TY5pcWKrdHnvckBw\iCqdX3hckBROzBvT1jLJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPi57ME[4JO69VS5?	M4OzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
GAMG	MmPiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG2MlkzPDNizszNMi=>	NFPS[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HCC1419	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkjETY5pcWKrdHnvckBw\iCqdX3hckBJS0NzNEG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPy54MUO5JO69VS5?	NGHiZYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SNU-C2B	NYPHSJRtT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWjGUpBxUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtR\|JDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNz63N\|c4KM7:TT6=	MnXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
MHH-NB-11	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHPPbHRKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3ORk0yOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUiuNVM5OyEQvF2u	NUH4OFg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
COLO-684	MnrMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVPvV2p2UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUiuNlM5OyEQvF2u	Ml7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OC-314	M{nzTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NILoSHJKdmirYnn0bY9vKG:oIHj1cYFvKE:FLUOxOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOThwM{W4JO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Becker	NE\peXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWnJcohq[mm2aX;uJI9nKGi3bXHuJGJm[2uncjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvPDZ{MzFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NCI-H1623	NX;1N3Q2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonSTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2NlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6Lk[zOlgh\|ryPLh?=	NUfLOndbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
IGROV-1	NV;nbWU3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH7FNGNKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF6Lk[1OVkh\|ryPLh?=	NInu[lU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
HSC-2	M4TCdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{LGXWlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5Njl3N{eg{txONg>?	NFLMWJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RMG-I	M4LNS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUHJcohq[mm2aX;uJI9nKGi3bXHuJHJOTy2LIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPU4yOzN6IN88UU4>	Ml\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CAL-120	M2LZUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3jjdmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUGyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTlwMkO1OEDPxE1w	NHLacnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GB-1	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWXUPVFpUW6qaXLpeIlwdiCxZjDoeY1idiCJQj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS55NES0JO69VS5?	NGT6OFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LU-139	MkPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF\|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlAvOThzNjFOwG0v	MnS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HT-1376	NIXlTG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1\pUWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUO3OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjBwNUe3NkDPxE1w	NIrsZYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW982	NGnkZZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn\3TY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlAvPjh\|NzFOwG0v	M1LUWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SK-N-FI	MnTGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH[wZ5NKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJzLkC4PFYh\|ryPLh?=	NXXjW\|A1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
SCC-9	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYn1ZXJZUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjFwMUSwPUDPxE1w	NEnxeHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW756	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIL6SIxKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS5{MUW2JO69VS5?	NGTK[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
SW948	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGT4TGRKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUS4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS53MkO2JO69VS5?	M4rSS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW1573	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXzX[FRvUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G1O\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJzLkizOFUh\|ryPLh?=	M3XadlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1792	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mmq4TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJzLki1OlUh\|ryPLh?=	NFntb3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
BE-13	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYnC[FhUUW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwNUi3N{DPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
SK-OV-3	MnHRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MojuTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOi55M{i4JO69VS5?	NIqwNIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
PA-1	NIHxWXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mlu0TY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyNk45PzF{IN88UU4>	NUfFU3JxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1693	NID5T4xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnHwTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2PVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ{LkmzNVMh\|ryPLh?=	M1LkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
no-10	NVjuTphlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHzLUIRKdmirYnn0bY9vKG:oIHj1cYFvKG6xLUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy5\|NUi4JO69VS5?	NUjndnRERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
JVM-2	M4HWZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXfldFB7UW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwNEG0O{DPxE1w	Ml\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SK-NEP-1	M2P3WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWXne3BOUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkOuOVIxPSEQvF2u	NHzT[mk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
PC-3	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV\rTYo1UW6qaXLpeIlwdiCxZjDoeY1idiCSQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy53N{KyJO69VS5?	M2DxSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
U-2-OS	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NETBUWxKdmirYnn0bY9vKG:oIHj1cYFvKFVvMj3PV{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwOES2PUDPxE1w	M1PRdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NBsusSR	NGn6RlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEPDcYtKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkGwOlIh\|ryPLh?=	M4rJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
EW-13	M1SxTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWTJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOE4yOzl6IN88UU4>	MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
BT-20	M{X0cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnrlTY5pcWKrdHnvckBw\iCqdX3hckBDXC1{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlQvPzF5ODFOwG0v	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MS-1	NULKVmZ4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3n3cGlvcGmkaYTpc44hd2ZiaIXtZY4hVVNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlUvODR7ODFOwG0v	MnrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
HCC1187	MoXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhESzFzOEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI2NjR2NUGg{txONg>?	M1iyelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TE-1	NFL4ToFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUTwfJRjUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS54OUWzJO69VS5?	M2TmOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
MKN7	MoPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmmzTY5pcWKrdHnvckBw\iCqdX3hckBOU055IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyOU44QTF\|IN88UU4>	MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H727	MmriS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1G1W2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3Nlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ4LkC1NVMh\|ryPLh?=	NHzGe449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
H4	MnrSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Nj6zO\|Y5KM7:TT6=	NXHD[FMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
647-V	NEDNOmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHnzSm1KdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPi56OEGxJO69VS5?	M13CclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
KM-H2	NXTwTWxpT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkT4TY5pcWKrdHnvckBw\iCqdX3hckBMVS2KMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlYvQTJ2IN88UU4>	NICyUW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ABC-1	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyO{4yQTd2IN88UU4>	NX;B[4JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
HCC1806	Mn3hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mm\GTY5pcWKrdHnvckBw\iCqdX3hckBJS0NzOEC2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy5\|NEKyJO69VS5?	NHjlOWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ES5	NG\MWmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NICweYtKdmirYnn0bY9vKG:oIHj1cYFvKEWVNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvPDl7OTFOwG0v	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
C3A	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXfJcohq[mm2aX;uJI9nKGi3bXHuJGM{SSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkeuOVY6PCEQvF2u	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
TE-10	NHjMfWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNTFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyO{43OzV4IN88UU4>	Moi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
S-117	M4nVdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVO4S3lWUW6qaXLpeIlwdiCxZjDoeY1idiCVLUGxO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjdwN{W3NUDPxE1w	M{HDZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
TGBC1TKB	NXz2N4c2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV7OS4FtUW6qaXLpeIlwdiCxZjDoeY1idiCWR1LDNXRMSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkeuPVkxOiEQvF2u	M1nVeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1793	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV7ydlVlUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE4QTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK4MlMxPzZizszNMi=>	NYjFRVBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
ES4	MmnFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{PvWWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPE44OzV{IN88UU4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
AN3-CA	NFTtT4ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1rQOWlvcGmkaYTpc44hd2ZiaIXtZY4hSU5\|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQC56NUmzJO69VS5?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
NMC-G1	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXjWc5dPUW6qaXLpeIlwdiCxZjDoeY1idiCQTVOtS\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ7LkGxNUDPxE1w	M4PTfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H226	M{PjeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3vPZWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ7LkK3NFEh\|ryPLh?=	MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H522	NHvzZYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUKyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQS56M{O5JO69VS5?	M3OzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
SW48	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkfkTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPU46OjV{IN88UU4>	NEXHe4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
OE33	NGnKfphIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJG9GOzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOwMlc6PTRizszNMi=>	MkDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
NCI-H2228	M1rJWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4j6c2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|MT6wN\|Q1KM7:TT6=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
D-423MG	NGnrSnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmLzTY5pcWKrdHnvckBw\iCqdX3hckBFNTR{M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS5yNU[0JO69VS5?	Mlm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
IST-MEL1	NGHJSIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWjpTZRoUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVNOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{GuNVUzQCEQvF2u	NXLT[m9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
A388	MlfjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWnTS2U6UW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS54MkO2JO69VS5?	NGCw[YI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
LN-405	Ml7TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGPKeHJKdmirYnn0bY9vKG:oIHj1cYFvKEyQLUSwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzFwN{m4N{DPxE1w	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
DMS-273	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mmi0TY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS57MUO4JO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
KS-1	NYS2NVdbT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV7UTZFHUW6qaXLpeIlwdiCxZjDoeY1idiCNUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Oy5zM{KxJO69VS5?	NH:4cY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
NCI-H209	NEnReJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXLVS5YzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iM{OuOFUyPyEQvF2u	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
HOS	M2TwTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NV;qPWl[UW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM{Njd{NUOg{txONg>?	NGroXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
GI-1	Mmr5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn7KTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzN{45ODdzIN88UU4>	MoXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
RERF-LC-MS	M{\xPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MljiTY5pcWKrdHnvckBw\iCqdX3hckBTTVKILVzDMW1UKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|ND6wN\|E2KM7:TT6=	NXLLZlltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H526	NVXtSZBnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC5yN{[g{txONg>?	NHS3NFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
RPMI-2650	NIK4TohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mmj2TY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUK2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2LkSzN\|Qh\|ryPLh?=	MoHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
KYSE-70	MkXoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml;5TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC56NEK2JO69VS5?	NIDEVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
Capan-2	MmLaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXXEW3ZJUW6qaXLpeIlwdiCxZjDoeY1idiCFYYDhck0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|Nj60OlUzKM7:TT6=	MlnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OVCAR-4	NE\sS\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnTzTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Py5{MUe2JO69VS5?	MoHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
OVCAR-8	MmD1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFywXIRKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN5Lkm4NlMh\|ryPLh?=	NVL3S2lSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
NCI-H1355	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlW0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN6LkGwOVEh\|ryPLh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
COLO-680N	NVLScIRFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVTh[Zp3UW6qaXLpeIlwdiCxZjDoeY1idiCFT1zPMVY5OE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO4MlI1OjlizszNMi=>	M1rQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H2122	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2HSNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|OT6zN\|Y{KM7:TT6=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
Saos-2	NHe2[2ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNid3NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|kvPzB3MzFOwG0v	M3PzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HCC2157	NFTaRYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MULJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJzNUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQxNjd5M{Sg{txONg>?	M3fvRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
VMRC-RCZ	M{f5cWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHzOd2lKdmirYnn0bY9vKG:oIHj1cYFvKF[PUlOtVmNbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2MT6yPVYzKM7:TT6=	NInVXGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
ETK-1	NIXHTJVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGVVUy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0NU42PzVzIN88UU4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
RCC10RGB	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2S0e2lvcGmkaYTpc44hd2ZiaIXtZY4hWkOFMUDSS2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR{LkCxPEDPxE1w	NHXtNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
KP-N-YS	NVrEXJc4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXzoVpREUW6qaXLpeIlwdiCxZjDoeY1idiCNUD3OMXlUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mj6wOlQyKM7:TT6=	NGXvZYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPjF2N{CxM{c,W0GQR1XSQE9iRg>?
T98G	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkHLTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0Nk43PzN\|IN88UU4>	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
A431	NYnSXpFMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NH;wepJKdmirYnn0bY9vKG:oIHj1cYFvKEF2M{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ2NjF6M{Gg{txONg>?	M4TkVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
HDLM-2	MofVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEHsXJJKdmirYnn0bY9vKG:oIHj1cYFvKEiGTF2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDVwMk[xO{DPxE1w	MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
CHP-134	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXTJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1zM{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ3NjF5N{mg{txONg>?	NYDkZ2VxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
J-RT3-T3-5	NFPQXYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUKyfJhSUW6qaXLpeIlwdiCxZjDoeY1idiCMLWLUN{1VOy13IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0Ok41PDZzIN88UU4>	M3rBN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE3OTR5MEGvK\|5USU6JRWK8M4E,
NCI-H1650	NI\tbIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mlf5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR4LkWxNFQh\|ryPLh?=	NYTCbJk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
MHH-PREB-1	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYDO[IkxUW6qaXLpeIlwdiCxZjDoeY1idiCPSFitVHJGSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0Ok42OjZ4IN88UU4>	MnOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SJRH30	MnTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGizZ\|VKdmirYnn0bY9vKG:oIHj1cYFvKFOMUlizNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{e3OUDPxE1w	MkfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
SF295	MlvtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn:yTY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFgvPTF7IN88UU4>	MoG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVYyPDdyMT:nQnNCVkeHUkyvZV4>
YAPC	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MY\Jcohq[mm2aX;uJI9nKGi3bXHuJHlCWENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES4Mlk1OiEQvF2u	NXjORXdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTZzNEewNU8oRlODTlfFVlww[T5?
EFM-19	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmPNTY5pcWKrdHnvckBw\iCqdX3hckBGTk1vMUmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjVyOEWg{txONg>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOlE1PzBzLze+V2FPT0WUPD;hQi=>
MIAPaCa2	MmS5VJJwdGmoZYLheIlwdiCjc4PhfS=>		NVPLOYFOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNTWFR[UOjMjDj[YxteyxiSVO1NF0yPDJibl2u	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR5NEO4PEc,OjN2N{SzPFg9N2F-
A375	NFrrd4JRem:uaX\ldoF1cW:wIHHzd4F6	M2HLPVczKGh?	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF\|N{WgZ4VtdHNiZYjwdoV{e2mwZzDCVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscEB1cXSncj3ncI8h[XO\|YYmsJGlEPTB;M{Ggcm0v	NGewPJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3OFM5QCd-MkO0O\|Q{QDh:L3G+
A549	NXznXohySW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlntRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|LDDJR\|UxKD1iMT63OUDPxE1w	NVvZfINERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
LoVo	Ml7SRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxVn:gZ4VtdHNuIFnDOVAhRSB{LkizJO69VS5?	M2rHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEe0N\|g5Lz5{M{S3OFM5QDxxYU6=
HCT116	Ml;3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mlf4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOg[ZhxemW\|c3nu[{BMWkGVIFexN2QhdXW2YX70MEBKSzVyIE2gN{4yKM7:TT6=	NW\kRopHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|Q{QDhpPkKzOFc1Ozh6PD;hQi=>
HeLa-MaTu	MV3GeY5kfGmxbjDhd5NigQ>?		MVPJcohq[mm2aX;uJI9nKE2HS{GgbY4hcHWvYX6gTIVN[S2PYWT1JI1ifGOqZXSgdIFqeiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSXJMKHCqb4PwbI9zgWyjdHnvckwhUUN3MDC9JFAvODF2IN88UU4>	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
HepG2	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NELnWHhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIhiemKxcnnu[{BPNVKjczDteZRifGmxbjygTWM2OCB;IECuNFMzKM7:TT6=	M1L0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkGxPVIxLz5{Nk[xNVkzODxxYU6=
COLO205	NImycHdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVroXoNFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGijcnLvdolv\yCEUlHGJI12fGG2aX;uMEBKSzVyIE2gNE4xPjlizszNMi=>	MlXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
A549	NHHNb21CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiaHHyZo9zcW6pIFutVoF{KG23dHH0bY9vNCCLQ{WwJF0hOS55NTFOwG0v	NGPaSIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkzOCd-Mk[2NVE6OjB:L3G+
HCT116	M{PF[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmXaRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgbIFz[m:{aX7nJGsuWmG\|IFexN2QhdXW2YYTpc44tKEmFNUCgQUA{KM7:TT6=	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4MUG5NlAoRjJ4NkGxPVIxRC:jPh?=
HeLa-MaTu-ADR	M2HOSWZ2dmO2aX;uJIF{e2G7		NXnFSmdwUW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKEinTHGtUYFVfS2DRGKgcYF1[2inZDDwZYlzKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFVmsheGixc4Doc5J6dGG2aX;uMEBKSzVyIE2gN{44KM7:TT6=	NHT1OG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[xNVkzOCd-Mk[2NVE6OjB:L3G+
SW480	NHfHUVRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	NHzUWIk4OiCqcoO=	M3G4OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2e0PFAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFIzKM7:TT6=	M1XTeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NES4PVE5Lz5{N{S0PFkyQDxxYU6=
SW620	NXjGbJV3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	NH\FcpI4OiCqcoO=	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZNkKwJINmdGy\|IHjhdoJwemmwZzDLVmFUKEdzMm[gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wNVUh\|ryPLh?=	MlrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{i5OFAoRjJ6MEO4PVQxRC:jPh?=
AsPC1	M4H0O2FvfGmycn;sbYZmemG2aY\lJIF{e2G7	MX63NkBpenN?	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEG\|UFOxJINmdGy\|IHjhdoJwemmwZzDLVmFUKEdzMlSgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6wOlQzKM7:TT6=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEm0NEc,OjhyM{i5OFA9N2F-
BA/F3	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MUS3NkBpenN?	Mn\jRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDoZZJjd3KrbnegT3JCWyCJMULEJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IECuNUDPxE1w	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB\|OEm0NEc,OjhyM{i5OFA9N2F-
SKCO1	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	MoTyO\|IhcHK\|	MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONQ1:xJINmdGy\|IHjhdoJwemmwZzDLVmFUKEdzMm[gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMD6xNVch\|ryPLh?=	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyM{i5OFAoRjJ6MEO4PVQxRC:jPh?=
COLO205	NH30em1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=	M{nxOlczKGi{cx?=	MnHURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFT1zPNlA2KGOnbHzzJIhiemKxcnnu[{BDWkGIIH31eIFvfC:5aXzkJJR6eGViS2LBV{94cWymIIT5dIUhWEmNM1PBJIFnfGW{IEeyJIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4xPTlizszNMi=>	NH20boc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOxO\|E1QCd-MkmzNVcyPDh:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK / β-catenin / E-cadherin / Vimentin / Fibronection; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 48 hours, and western blot analysis was performed, with β-actin used as a loading control. pS6(235/236) / pS6(240/244); PubMed: 26137449 Mol Cancer Ther Selumetinib (Sel) in combination with BEZ235 or ZSTK474 inhibits pS6 expression in BRAF-mutant melanoma cell lines that are highly sensitive (NZM3, NZM11, NZM20) or moderately sensitive (NZM6, NZM7, NZM12) to single agent selumetinib. Cells were treated with 500 nM of each compound as indicated for 1 or 24 h. Blots are representative images of two independent determinations. pVEGFR(Y1175) / VEGFR2 / pPDGFRβ(Y751) / pPDGFRβ / pAXL(Y702) / AXL / pMEK / MEK; PubMed: 22500798 Cell Dose-dependent RTK reprogramming in response to AZD6244. Dose-dependent induction of RTK expression and activity in 24h-treated SUM159 cells was determined by western blot. Bak / Bad / Bcl-xl / BimEL / BimL / BimS / PUMA / NOXA ; PubMed: 20885957 PLoS One Human lung cancer cell lines (Calu-6, H2347, and H3122) were treated with 3 µM AZD6244 for 4, 8, 24, 48, and 72 hours. Western blots of Bcl-2 family members after treatment with AZD6244.	26384399 26137449 22500798 20885957
Immunofluorescence	β-catenin; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib in a 3D culture for 48 hours. Immunofluorescence staining was done to detect β-catenin-FITC (fluorescein isothiocyanate), and nuclei were stained with DAPI. Images were taken under 60× magnification. FOXO3a; PubMed: 20885957 PLoS One Subcellular localization of FOXO3a in Calu-6 and H522 cells was detected with immunofluorescence staining after AZD6244 treatment.	26384399 20885957
Growth inhibition assay	Cell viability; PubMed: 26384399 Mol Cancer Ther MDA-MB-231 and SUM149 cells were treated with selumetinib for 72 hours, and then cell viability was measured using the WST-1 assay.	26384399

In vivo

AZD6244 significantly inhibits phosphorylation of ERK1/2 in 2-1318, 5-1318, 26-1004 and 4-1318 xenografts and induces apoptosis in primary 2-1318 cells by activating the caspase pathway. ^[1] AZD6244 could inhibit the tumor growth in HT-29 xenograft, which is a colorectal tumor model carrying a B-Raf mutation, at a dose of 100 mg/kg and the tumor growth inhibition of AZD6244 is better than it of Gemcitabine. ^[3] Otherwise AZD6244 could inhibit HCC xenografts tumor growth, which associated with increased apoptosis and down-regulation of cell cycle regulators, including cyclin D1, Cdc-2, CDK2 and 4, cyclin B1, and c-Myc. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Assay of MEK Kinase Activity: Anti-MEK1 antibody is used to immunoprecipitate MEK1 molecules. MEK kinase activity is measured as the ability of immuno-isolated MEK1 to activate recombinant ERK1 in a coupled assay using MBP as the end point of the assay. Phosphorylated MBP is resolved on a 14% SDS-PAGE gel and vacuum-dried before exposure to X-ray film.
Cell Research: ^[1]	- Collapse Cell lines: Primary HCC cell lines including 2-1318, 4-1318 and 26-1004 cells Concentrations: ~ 10 μM Incubation Time: 24 or 48 hours Method: Cells are seeded at a density of 2.0 × 10⁴. After 48 hours incubation, the cells are rinsed twice with culture media. Cells are treated with various concentrations of AZD6244 for 24 or 48 hours. Cell viability is determined by the 3-(4,5-dimethylthiazol-2y1)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell proliferation is assayed using a bromodeoxyuridine kit. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: HCC xenografts in mice homozygous for the SCID (severe combined immunodeficiency) mutation Dosages: 50 or 100mg/kg Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (198.82 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Selumetinib (AZD6244) SDF

Molecular Weight	457.68
Formula	C₁₇H₁₅BrClFN₄O₃
CAS No.	606143-52-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	ARRY-142886
Smiles	CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04879160	Recruiting	--	Neurofibromatosis 1	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 12 2021	--
NCT04590235	Recruiting	Drug: Selumetinib	Neurofibromatosis 1\|Neurofibroma Plexiform	AstraZeneca\|Merck Sharp & Dohme Corp.	December 16 2020	Phase 1
NCT03433183	Recruiting	Drug: Selumetinib\|Drug: Sirolimus	Malignant Peripheral Nerve Sheath Tumors\|Neurofibromatosis 1	Sarcoma Alliance for Research through Collaboration\|United States Department of Defense\|AstraZeneca	October 2 2019	Phase 2
NCT03326388	Recruiting	Drug: Selumetinib	Neurofibromatosis Type 1\|Plexiform Neurofibroma\|Optic Nerve Glioma	Great Ormond Street Hospital for Children NHS Foundation Trust\|AstraZeneca	September 26 2019	Phase 1\|Phase 2
NCT03833427	Active not recruiting	Drug: Selumetinib\|Biological: Pembrolizumab	Advanced/Metastatic Solid Tumors	Merck Sharp & Dohme Corp.	March 18 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How about the solubility of S1008? How to prepare for the solution if I need to do the in vivo experiments?
Answer:
S1008 AZD6244 in vehicle 5% DMSO+30% PEG 300+ddH2O will be a suspension for oral administration. If you want a clear solution for injection, you can dissolve it in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Pan MEK Inhibitor

U0126-EtOH : MEK1, IC50=0.07 μM; MEK2, IC50=0.06 μM,
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212, JTP-74057, Mekinist) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Features:Does not inhibit c-Raf phosphorylated MEK1.
PD184352 (CI-1040)

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Features:First MEK inhibitor to begin clinical development.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

Selumetinib (AZD6244)